Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.05.2024 | Case report

Durvalumab

Non-tuberculous mycobacteria lung disease due to Mycobacterium chimaera

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Azzara C, et al. Non-tuberculous mycobacteria lung disease due to Mycobacterium chimaera in a 67-year-old man treated with immune checkpoint inhibitors for lung adenocarcinoma: infection due to dysregulated immunity?. BMC Infectious Diseases 23 : 1-5, Dec 2023. Available from: URL: https://dx.doi.org/10.1186/s12879-023-08537-w Azzara C, et al. Non-tuberculous mycobacteria lung disease due to Mycobacterium chimaera in a 67-year-old man treated with immune checkpoint inhibitors for lung adenocarcinoma: infection due to dysregulated immunity?. BMC Infectious Diseases 23 : 1-5, Dec 2023. Available from: URL: https://​dx.​doi.​org/​10.​1186/​s12879-023-08537-w
Metadaten
Titel
Durvalumab
Non-tuberculous mycobacteria lung disease due to Mycobacterium chimaera
Publikationsdatum
01.05.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-58145-9

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Multiple drugs

Case report

Multiple drugs

Case report

Multiple drugs

Case report

Rivaroxaban

Case report

Belatacept